{"schema":"sb.node.v1","id":"sb:e/2201f0261dd930f9677e6578","kind":"entity","label":{"text":"egfr","locale":"en"},"identity":{"anchor":"label:en:egfr","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T13:13:12.220585+00:00","snapshot":"deploy 0179e3ac7995bc9e92bae3a80f173732f24a5d75"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":160,"separatePublishers":53,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":12,"of":12,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-12","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.194: about 81% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","precision_medicine","pubmed_targeted"],"activeDays":74,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/3b8c5befd13f379775fbe82a","kind":"observation","label":"AllSci News · 2026-10-07 · ArriVent's firmonertinib falls short in global Phase III EGFR exon 20 trial","url":"https://allsci.com/news/clinical-trials/furvent-trial-failure-stalls-firmonertinibs/"},{"id":"sb:o/be9b93e327da1abb5f0ed25f","kind":"observation","label":"Oncologist · 2026-10-03 · REVERCE II: A Phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer.","url":"https://doi.org/10.1093/oncolo/oyag307"},{"id":"sb:o/1af8d23d18fa643342465611","kind":"observation","label":"Colorectal Dis · 2026-10-01 · Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study.","url":"https://doi.org/10.1111/codi.70639"},{"id":"sb:o/0ccfc7bd5c2e2603b4f1dbf5","kind":"observation","label":"bioRxiv Cancer Biology · 2026-09-25 · Disrupting aberrant EGFR catalytic trimers reverses T790M gefitinib resistance","url":"https://www.biorxiv.org/content/10.64898/2026.09.24.754095v1?rss=1"},{"id":"sb:o/37004ea0d9783d52f09de05f","kind":"observation","label":"Int J Clin Pharmacol Ther · 2026-09-25 · Anti-EGFR antibody therapy and skin toxicity: Retrospective analysis and role of pharmacists in protocol-based pharmacotherapy management.","url":"https://doi.org/10.5414/CP205030"},{"id":"sb:o/c3d6a724542b82b169ddd6a2","kind":"observation","label":"European Medical Journal · 2026-09-24 · Probiotic Supplementation Improves eGFR in Moderate CKD","url":"https://www.emjreviews.com/nephrology/news/probiotic-supplementation-improves-egfr-in-moderate-ckd/"},{"id":"sb:o/d2a5e052bb73bfa20a863f72","kind":"observation","label":"Inside Precision Medicine · 2026-09-24 · Inherited EGFR Mutation Raises Lung Cancer Risk in Nonsmokers","url":"https://www.insideprecisionmedicine.com/topics/oncology/inherited-egfr-mutation-raises-lung-cancer-risk-in-nonsmokers/"},{"id":"sb:o/9dd18272045fbcf3f2b6537c","kind":"observation","label":"Funct Integr Genomics · 2026-09-23 · Mutations in untranslated non-coding regions of EGFR, AKT1 & HRAS modulate their expression regulatory networks to facilitate progression of colorectal cancer.","url":"https://doi.org/10.1007/s10142-026-02050-4"},{"id":"sb:o/3f0ddecd9a7d937eed5aa919","kind":"observation","label":"Clinical Colorectal Cancer · 2026-09-20 · EGFR targeting with afatinib and cetuximab versus cetuximab alone in chemorefractory wild-type RAS metastatic colorectal cancer. A randomized phase II study …","url":"https://www.sciencedirect.com/science/article/pii/S1533002826000691?dgcid=rss_sd_all"},{"id":"sb:o/ccae0c51fc762242acabd0a0","kind":"observation","label":"The ASCO Post · 2026-09-18 · Metastatic EGFR-Mutated NSCLC Global Study of Izalontamab Brenitecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-egfr-mutated-nsclc-global-study-of-izalontamab-brenitecan/"}],"cursor":"c1.eyJpZCI6InNiOmUvMjIwMWYwMjYxZGQ5MzBmOTY3N2U2NTc4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDEzOjEzOjEyLjIyMDU4NSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":{"state":"cannot-measure","reason":"claims: this subject's maintained record could not be read (the maintained record \"egfr\" could not measure its claims: this subject was retired from the publication registry on 2026-09-30 (no longer clears the admission conditions — re-checked 2026-09-30 (no receipt in the corpus-evidence shard for this label)); the record is kept as a dated tombstone and is no longer maintained). The items listed come from the passes that could be read"},"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with colorectal cancer (69 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/6f5fb8921e89eba2c4c83610"},{"kind":"relation","label":"co-mentioned with lung cancer (63 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8921da480b9ae69ef69be796"},{"kind":"relation","label":"co-mentioned with immunotherapy (46 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fd90e6898381600a3482ca4c"},{"kind":"relation","label":"co-mentioned with studie (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d8548f832c5bb9d509418cef"},{"kind":"relation","label":"co-mentioned with fda (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1f4df3ea3b36d569ed404e36"},{"kind":"relation","label":"co-mentioned with her2 (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3acc259d344f5d4b5d3211f9"},{"kind":"relation","label":"co-mentioned with china (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dca399906660f5fbff7dfd77"},{"kind":"relation","label":"co-mentioned with braf (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/38b901852a2dcf6c11b4b942"},{"kind":"relation","label":"co-mentioned with kras (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e48ba47d5ab3e22994704e75"},{"kind":"relation","label":"co-mentioned with egfr-mutated (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d35735e0da9214b223606828"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/2201f0261dd930f9677e6578","mcp":"traverse {\"id\":\"sb:e/2201f0261dd930f9677e6578\"}","page":"/entity/egfr/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2201f0261dd930f9677e6578\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2201f0261dd930f9677e6578\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2201f0261dd930f9677e6578\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2201f0261dd930f9677e6578\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}